𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HIV-1 Intergrase Inhibitors: 2003—2004 Update

✍ Scribed by Raveendra Dayam; Jinxia Deng; Nouri Neamati

Publisher
John Wiley and Sons
Year
2006
Weight
8 KB
Volume
37
Category
Article
ISSN
0931-7597

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HIV-1 integrase inhibitors: 2003–2004 up
HIV-1 integrase inhibitors: 2003–2004 update
✍ Raveendra Dayam; Jinxia Deng; Nouri Neamati 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 906 KB

## Abstract The integration of viral cDNA into the host genome is an essential step in the HIV‐1‐life cycle and is mediated by the virally encoded enzyme, integrase (IN). Inhibition of this process provides an attractive strategy for antiviral drug design. The discovery of β‐diketo acid inhibitors

HIV-1 integrase inhibitors: 2005–2006 up
HIV-1 integrase inhibitors: 2005–2006 update
✍ Raveendra Dayam; Rambabu Gundla; Laith Q. Al-Mawsawi; Nouri Neamati 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 813 KB

## Abstract HIV‐1 integrase (IN) catalyzes the integration of proviral DNA into the host genome, an essential step for viral replication. Inhibition of IN catalytic activity provides an attractive strategy for antiretroviral drug design. Currently two IN inhibitors, MK‐0518 and GS‐9137, are in adva

HIV-1 integrase inhibitors: 2007–2008 up
HIV-1 integrase inhibitors: 2007–2008 update
✍ Kavya Ramkumar; Erik Serrao; Srinivas Odde; Nouri Neamati 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 892 KB

In recent years, HIV-1 integrase (IN) has become an attractive target for designing antiretroviral agents. The first IN inhibitor approved for clinical use, raltegravir, has validated the pharmacological viability of IN inhibitors and signals the advent of a new generation of antiretroviral drugs. T